Histone acetyltransferase MYST3 plays an important role in breast cancer development and activation of ER expression, and targeting MYST3 may serve as a novel strategy to block ER expression in MYST3-high ER+/HER2− breast tumors [65]. Here, KAT6A is linked to breast carcinoma.